Abstract: Provided is a compound which has strong intraocular pressure lowering action and has no side effect on eyes such as ocular stimulating property, humor protein rise etc. Since a compound represented by the formula (I): (wherein definition of each group is as described in the specification), or a salt thereof, a solvate thereof, or a prodrug thereof has strong intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
Abstract: The present invention is directed to a pharmaceutical composition comprising the following compound or a pharmaceutically acceptable salt thereof. The compound is a modulator of Nrf2 protein and binds at least one of the BTB domain, IVR domain and Kelch domain of Keap1 protein, activating or inhibiting Nrf2.
Abstract: An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%.
Abstract: The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
Type:
Grant
Filed:
December 22, 2011
Date of Patent:
August 11, 2015
Assignee:
LEO LABORATORIES LIMITED
Inventors:
Gunnar Grue-Sørensen, Xifu Liang, Thomas Högberg, Kristoffer Månsson, Per Vedsø, Thomas Vifian
Abstract: Described herein are compounds, compositions, and methods useful for treating bone diseases or defects. Also described herein are compounds, compositions and methods for treating bone diseases or defects by inhibiting phosphatase complexes.
Type:
Grant
Filed:
July 24, 2009
Date of Patent:
June 16, 2015
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
Abstract: The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT) by administering to the patient and effective amount of 1-alkyl, 2-acyl-glycerol.
Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2 and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are inhibitors of Cathepsin C.
Type:
Grant
Filed:
September 14, 2012
Date of Patent:
April 7, 2015
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Marc Grundl, Thorsten Oost, Alexander Pautsch, Stefan Peters, Doris Riether, Wolfgang Wienen
Abstract: The present invention directed to a method of treating multiple myeloma with the following compound: or a pharmaceutically acceptable salt thereof. The compound is a novel small molecule inhibitor of Ire1.
Type:
Grant
Filed:
November 8, 2011
Date of Patent:
March 31, 2015
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.
Abstract: The present invention is directed to compounds of Formula I: wherein R1, R2, R3, R4, R5, X and n are described herein. These compounds and their pharmaceutically acceptable salts thereof are useful as IK1 channel activators.
Abstract: The present invention is directed to the treatment of demyelination as an underlying cause of the disease of multiple sclerosis (MS) in a mammal, the method comprising promoting remyelination of myelination of axonal cells by administering to the mammal a 2-oxopyrrolidine compound having a general formula I: wherein R?R??H, and R??CH2CONH-(2,6CH3)C6H3 or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
October 22, 2010
Date of Patent:
February 24, 2015
Assignee:
University College Dublin, National University of Ireland, Dublin
Abstract: The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
Abstract: The present invention relates to benzofuran-2-sulfonamide derivatives with the following formula: or pharmaceutically acceptable salts thereof. The derivatives are useful as modulators of chemokine receptors.
Type:
Grant
Filed:
March 1, 2013
Date of Patent:
January 6, 2015
Assignee:
Allergan, Inc.
Inventors:
Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.
Type:
Grant
Filed:
July 1, 2013
Date of Patent:
December 30, 2014
Assignee:
Plus Chemicals SA
Inventors:
Ondrej Simo, Pavel Vraspir, Tomas Holas, Alexandr Jegorov, Roman Gabriel
Abstract: The present disclosure relates to compositions comprising formic acid as an active ingredient and a softening agent or emollient for use in the treatment of fungal infections of the skin and/or nail(s) of mammals, as well as methods for treatment utilizing such compositions.
Abstract: The present invention relates to a compound represented by general formula I: or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, A6, R2, R7, W, X, Y and Z are defined within. These compounds are useful for the modulation of ?-secretase enzyme activity and for the treatment of ?-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions.
Type:
Grant
Filed:
August 4, 2011
Date of Patent:
December 30, 2014
Assignee:
Amgen Inc.
Inventors:
Ana Elena Minatti, Yuan Cheng, Wenge Zhong
Abstract: The present invention relates to a compound of Formula (I) or (II) or a salt thereof, wherein R is described herein. The compounds are novel hydroxy-proline analog inhibitors of the ASCT1 and ASCT2 neutral amino acid transporters.
Type:
Grant
Filed:
July 16, 2012
Date of Patent:
November 25, 2014
Assignee:
The University of Montana
Inventors:
Michael P. Kavanaugh, Brent Lyda, Nicholas R. Natale, Stephanie Lynn Martinelli
Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.